Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs on Two PPOs for Coverage of Cancer MDx

NEW YORK (GenomeWeb News) –Rosetta Genomics today announced it has executed credentialing agreements with two preferred provider organizations for its Cancer Origin Test.

Today's deals are with FedMed and Fortified Provider Network and bring the number of PPOs with which Rosetta has executed credentialing agreements to four. In June the Rehovot, Israel-based company signed an agreement with Three Rivers Provider Network, and in May it inked a deal with Prime Health Services.

Along with Medicare reimbursement, the total number of potential covered lives for which the Cancer Origin Test could be adjudicated as in-network is estimated at more than 100 million, Rosetta's President and CEO Kenneth Berlin said.

"We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials. This has become increasingly important to our company as we have expanded our US commercial operations and continue to process and bill a growing number of samples," he said in a statement.

FedMed has more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers nationwide. According to Rosetta, more than 40 million Americans are estimated to have access to FedMed's National Provider Network.

Fortified is a national direct-contracted PPO representing about 4 million covered lives. Its network is used by self-funded employer groups, insurance carriers, and regional and local provider networks that process end-user patient claims.

Rosetta's Cancer Origin Test is a microRNA-based molecular diagnostic that is used to identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary. It was formerly called the miRview mets2 test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.